Home / Stocks / SUPN

Supernus Pharmaceuticals (SUPN, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Supernus Pharmaceuticals (SUPN, Pharmaceuticals) trades at a blended P/E of 15.2, about 27% below its historical normal valuation, with a forward growth estimate of 34.2% and a PEG of 0.45. Priced at its historical normal P/E of 20.8 on the same blended earnings, the 2026-09-18 close of $42.00 corresponds to about $57.30 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
15.2
Normal P/E
20.8
PEG
0.45
Fwd growth
34.2%
Div yield
0.0%
RSI (14)
48.4
Neutral
Technical context
  • Price $43.39 at the 2026-09-23 close, 0.8% above the 20-day average ($43.04) and 4.4% below the 50-day ($45.41).
  • RSI (14) at 48.4.
  • 52-week range $41.28 to $57.00: the price is 23.9% below the high and 5.1% above the low.

The Street vs SeerForecast

Wall Street's mean price target for SUPN is $61.75 across 4 analysts, 42.3% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 16.6 to 15.2 between 2026-07-31 and 2026-09-21, against a normal P/E of 20.8, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 16.6, Fairly valued (recalculated)2026-08-03: P/E 16.2, Fairly valued2026-08-07: P/E 16.2, Fairly valued (recalculated)2026-08-10: P/E 16.8, Fairly valued2026-08-14: P/E 16.8, Fairly valued (recalculated)2026-08-17: P/E 17.1, Fairly valued2026-08-21: P/E 17.1, Fairly valued (recalculated)2026-08-24: P/E 16.3, Fairly valued2026-08-27: P/E 16.3, Fairly valued (recalculated)2026-08-28: P/E 16.3, Fairly valued (recalculated)2026-08-30: P/E 16.3, Fairly valued (recalculated)2026-08-31: P/E 15.7, Fairly valued2026-09-05: P/E 15.7, Fairly valued (recalculated)2026-09-07: P/E 15.7, Fairly valued2026-09-12: P/E 15.7, Fairly valued (recalculated)2026-09-14: P/E 15.0, Fairly valued2026-09-19: P/E 15.0, Fairly valued (recalculated)2026-09-21: P/E 15.2, Fairly valued16.018.020.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 20.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 16.6-20%Fairly valued
2026-08-17P/E 17.1-18%Fairly valued
2026-09-14P/E 15.0-28%Fairly valued
2026-09-21P/E 15.2-27%Fairly valued ← now

Frequently asked questions

Is Supernus Pharmaceuticals stock overvalued?

At a blended P/E of 15.2 versus its historical normal P/E of 20.8, Supernus Pharmaceuticals trades about 27% below its typical valuation, with a PEG of 0.45 on 34.2% forward growth. tickerseer currently rates it fairly valued.

What is Supernus Pharmaceuticals's fair value and PEG?

Supernus Pharmaceuticals trades at a blended P/E of 15.2 against a historical normal P/E of 20.8, a PEG of 0.45, and a forward growth estimate of 34.2%. Priced at its historical normal P/E of 20.8 on the same blended earnings, the 2026-09-18 close of $42.00 corresponds to about $57.30 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Supernus Pharmaceuticals changed?

tickerseer's rating has been fairly valued since 2026-07-31.

What is the analyst price target for Supernus Pharmaceuticals?

The mean Wall Street price target for Supernus Pharmaceuticals is $61.75 across 4 analysts, 42.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SUPN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.